Literature DB >> 15075660

Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections.

Philippe Montravers1, Annie Chalfine, Remy Gauzit, Alain Lepape, Jean Pierre Marmuse, Corinne Vouillot, Claude Martin.   

Abstract

OBJECTIVE: To compare the clinical, microbiological, and therapeutic features of nonpostoperative nosocomial intra-abdominal infections (non-PostopNAI) with community-acquired intra-abdominal infections (CAI). SUMMARY BACKGROUND DATA: Prospective (June 2000 through January 2001) consecutive case series analysis of patients operated for secondary nonpostoperative intra-abdominal infections collected in 176 study centers (surgical wards and intensive care units). PATIENTS AND METHODS: Clinical, microbiological, and therapeutic characteristics of CAI and non-PostopNAI infections were collected. Management of antibiotic therapy was decided by the attending physician. The efficacy of treatment was evaluated over a 30-day period after the index episode.
RESULTS: Evaluatable observations (n = 1008) were collected (761 CAI and 247 non-PostopNAI), including 285 intensive care unit patients. When compared with CAI patients, non-PostopNAI patients presented an increased interval between admission to the surgical ward and operation (1.3 +/- 1.5 vs. 0.5 +/- 0.7 days in CAI patients; P < 0.001), increased proportions of underlying diseases, a more severe clinical condition as assessed by increased proportions of hospitalization in the intensive care unit (48% vs. 22% in CAI patients, P < 0.001) and a higher SAPS II score (34 +/- 15 vs. 24 +/- 14, P < 0.001). In non-PostopNAI patients, increased proportions of therapeutic failure (15% vs. 7% in CAI patients, P < 0.01) and of fatalities (12% vs. 4% in CAI patients, P < 0.001) were observed.
CONCLUSIONS: Delayed diagnosis and increased severity are the main characteristics of non-PostopNAI infections. Microbiological features are quite similar in CAI and non-PostopNAI infections, suggesting that antibiotic therapy recommended for CAI infections could be applied to non-PostopNAI patients. Characteristics of non-PostopNAI patients should lead to identify them as a specific entity in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15075660      PMCID: PMC1356241          DOI: 10.1097/01.sla.0000114214.68169.e9

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  27 in total

Review 1.  Management of community-acquired peritonitis. Short text.

Authors: 
Journal:  Ann Fr Anesth Reanim       Date:  2001-11

2.  Perforated or gangrenous appendicitis treated with aminoglycosides. How do bacterial cultures influence management?

Authors:  S H Dougherty; E C Saltzstein; J B Peacock; L C Mercer; P Cano
Journal:  Arch Surg       Date:  1989-11

3.  Diagnostic and therapeutic management of nosocomial pneumonia in surgical patients: results of the Eole study.

Authors:  Philippe Montravers; Benoit Veber; Christian Auboyer; Hervé Dupont; Remy Gauzit; Anne Marie Korinek; Yannick Malledant; Claude Martin; Pierre Moine; Jean Louis Pourriat
Journal:  Crit Care Med       Date:  2002-02       Impact factor: 7.598

Review 4.  Role of aminoglycoside antibiotics in the treatment of intra-abdominal infection.

Authors:  J L Ho; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

5.  Critical importance of early diagnosis and treatment of intra-abdominal infection.

Authors:  W D Pitcher; D M Musher
Journal:  Arch Surg       Date:  1982-03

6.  The microbiology of postoperative peritonitis.

Authors:  A Roehrborn; L Thomas; O Potreck; C Ebener; C Ohmann; P E Goretzki; H D Röher
Journal:  Clin Infect Dis       Date:  2001-09-24       Impact factor: 9.079

7.  Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group.

Authors:  H Dupont; C Carbon; J Carlet
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

8.  Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998.

Authors:  A C Fluit; M E Jones; F J Schmitz; J Acar; R Gupta; J Verhoef
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

9.  Prognosis in generalized peritonitis. Relation to cause and risk factors.

Authors:  J Bohnen; M Boulanger; J L Meakins; A P McLean
Journal:  Arch Surg       Date:  1983-03

10.  Timentin in the antimicrobial treatment of nosocomial and polymicrobial infections.

Authors:  J Carlet; F W Goldstein; J P Blériot; F Bahloul; F E Dazza
Journal:  J Antimicrob Chemother       Date:  1986-05       Impact factor: 5.790

View more
  13 in total

1.  Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections.

Authors:  Moshe Schein
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

2.  Canadian practice guidelines for surgical intra-abdominal infections.

Authors:  Anthony W Chow; Gerald A Evans; Avery B Nathens; Chad G Ball; Glen Hansen; Godfrey Km Harding; Andrew W Kirkpatrick; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

3.  When and how to cover for fungal infections in patients with severe sepsis and septic shock.

Authors:  Nicolas Allou; Jerome Allyn; Philippe Montravers
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

4.  Impact of Surgical Infection Society/Infectious Disease Society of America-recommended antibiotics on postoperative intra-abdominal abscess with image-guided percutaneous abscess drainage following gastrointestinal surgery.

Authors:  Yoshiki Okita; Minako Kobayashi; Toshimitsu Araki; Hiroyuki Fujikawa; Yuhki Koike; Koike Yuki; Kohei Otake; Otake Kohei; Inoue Mikihiro; Inoue Mikihiro; Yuji Toiyama; Toiyama Yuji; Masaki Ohi; Msaki Ohi; Koji Tanaka; Yasuhiro Inoue; Keiichi Uchida; Yasuhiko Mohri; Koichiro Yamakado; Masato Kusunoki
Journal:  Surg Today       Date:  2014-10-18       Impact factor: 2.549

5.  Choosing antibiotics for intra-abdominal infections: what do we mean by "high risk"?

Authors:  Brian R Swenson; Rosemarie Metzger; Traci L Hedrick; Shannon T McElearney; Heather L Evans; Robert L Smith; Tae W Chong; Kimberley A Popovsky; Timothy L Pruett; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2009-02       Impact factor: 2.150

6.  Compliance with an empirical antimicrobial protocol improves the outcome of complicated intra-abdominal infections: a prospective observational study.

Authors:  M Guilbart; E Zogheib; A Ntouba; L Rebibo; J M Régimbeau; Y Mahjoub; H Dupont
Journal:  Br J Anaesth       Date:  2016-07       Impact factor: 9.166

7.  WSES consensus conference: Guidelines for first-line management of intra-abdominal infections.

Authors:  Massimo Sartelli; Pierluigi Viale; Kaoru Koike; Federico Pea; Fabio Tumietto; Harry van Goor; Gianluca Guercioni; Angelo Nespoli; Cristian Tranà; Fausto Catena; Luca Ansaloni; Ari Leppaniemi; Walter Biffl; Frederick A Moore; Renato Poggetti; Antonio Daniele Pinna; Ernest E Moore
Journal:  World J Emerg Surg       Date:  2011-01-13       Impact factor: 5.469

8.  Can yeast isolation be predicted in complicated secondary non-postoperative intra-abdominal infections?

Authors:  Hervé Dupont; Mathieu Guilbart; Alexandre Ntouba; Mélanie Perquin; Sandra Petiot; Jean-Marc Regimbeau; Taieb Chouaki; Yazine Mahjoub; Elie Zogheib
Journal:  Crit Care       Date:  2015-02-27       Impact factor: 9.097

9.  Clinical and economic consequences of failure of initial antibiotic therapy for patients with community-onset complicated intra-abdominal infections.

Authors:  Yong Pil Chong; In-Gyu Bae; Sang-Rok Lee; Jin-Won Chung; Jae-Bum Jun; Eun Ju Choo; Soo-youn Moon; Mi Suk Lee; Min Hyok Jeon; Eun Hee Song; Eun Jung Lee; Seong Yeon Park; Yang Soo Kim
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

Review 10.  Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections.

Authors:  Kellie J Goodlet; David P Nicolau; Michael D Nailor
Journal:  Ther Clin Risk Manag       Date:  2016-12-01       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.